Lantern Pharma Reports Complete Response in Heavily Pre-Treated Lymphoma Patient with LP-284 in Phase 1 Clinical Trial
This extraordinary clinical observation represents a transformative moment for our computationally guided, therapeutic development paradigm
Share
The RADR®-driven, AI approach enables Lantern to rapidly determine mechanisms of action of any cancer focused molecule, identify biomarker-driven subpopulations and optimize combination strategies for the clinical setting.
The 41-year-old patient had previously failed three aggressive treatment regimens over 18 months over the last 15 months. These included: standard R-CHOP/Pola-R-CHP chemotherapy, CAR-T cell therapy (liso-cel), and CD3xCD20 bispecific antibody therapy (glofitamab). Following enrollment in April 2025, the patient achieved complete metabolic response with non-avid lesions after completing just two 28-day cycles of LP-284 administered on days one, eight, and 15. This remarkable clinical outcome supports LP-284's synthetic lethal mechanism and is an initial step towards a potential new paradigm for treating refractory aggressive lymphomas and B-cell malignancies.
Paradigm-Shifting Observation of Complete Response in Therapeutically Exhausted Patient
'This extraordinary clinical observation represents a transformative moment for our computationally guided, therapeutic development paradigm,' said Panna Sharma, President and CEO of Lantern Pharma. 'Our RADR® platform's systematic analysis of molecular vulnerabilities enabled us to rapidly advance LP-284 from computational concept to a clinical milestone in a patient in under three years at approximately $3 million — demonstrating how AI-driven precision has the promise to fundamentally reshape pharmaceutical innovation. This complete metabolic response in a patient who had exhausted all conventional therapeutic options strongly supports our strategic thesis that computational approaches can unlock previously inaccessible therapeutic opportunities.'
LP-284, a computationally optimized next-generation acylfulvene, was systematically developed with guidance from Lantern's RADR® platform to exploit synthetic lethal interactions in cancer cells harboring specific DNA damage repair deficiencies. The compound represents a fundamentally different therapeutic strategy with the potential to preferentially target malignant cells while preserving healthy tissue function — a precision approach aimed at delivering transformative clinical benefit for patients who have failed multiple prior treatment modalities.
Potential to Address a Critical Therapeutic Void in Refractory DLBCL
This patient's clinical journey exemplifies the devastating trajectory of aggressive DLBCL in the refractory setting. Despite achieving an initial complete metabolic response with CAR-T therapy (liso-cel) at day 30, the patient experienced disease progression by day 90. Subsequent treatment with the CD3xCD20 bispecific antibody glofitamab resulted in progressive disease with multifocal new lesions. At study entry on the LP-284-Phase 1 trial in April 2025, the patient presented with extensive multifocal bony lesions across thoracic and lumbar spine locations and hips — representing an extremely challenging clinical scenario.
The achievement of complete metabolic response with non-avid lesions following just two cycles of LP-284 therapy represents a potential future paradigm-shifting alternative for treating therapeutically exhausted DLBCL patients. This encouraging outcome underscores LP-284's potential to address critical gaps in the therapeutic armamentarium for patients who have failed both conventional and cutting-edge immunotherapeutic approaches.
Advancing Strategic Clinical Development and Global Expansion
The complete metabolic response achievement positions LP-284 for accelerated development pathways and strengthens Lantern's strategic position in the competitive hematologic oncology landscape. This clinical milestone provides important confirmation of the company's systematic approach to therapeutic development and creates additional opportunities for international partnership expansion and collaborative research initiatives.
Lantern's ongoing Phase 1 dose-escalation study (NCT06132503) is designed to evaluate LP-284's safety profile, optimal dosing parameters, and preliminary efficacy signals across multiple aggressive lymphoma subtypes.
The trial's systematic design enables precise evaluation of LP-284's therapeutic potential across genetically defined patient populations, with a current focus on aggressive NHL subtypes including mantle cell lymphoma and high-grade B-cell lymphomas. LP-284's multiple FDA Orphan Drug Designations position the compound for potential expedited regulatory pathways and enhanced market exclusivity frameworks.
Transforming Global Oncology Through Computational Precision
This clinical development provides important confirmation of the transformative potential of Lantern's RADR® platform, which leverages over 200 billion oncology-focused data points and 200+ machine learning algorithms to assist in systematically identifying and optimizing therapeutic opportunities. The platform's computational efficiency enabled Lantern to rapidly advance the LP-284's program into the clinic in under three years at a cost of approximately $3 million — representing striking development efficiency compared to traditional pharmaceutical paradigms.
The complete metabolic response achievement positions LP-284 to seek a future role within a global blood cancer market focused on B-cell cancer that is estimated at $4 billion annually, with DLBCL representing the largest aggressive lymphoma subtype affecting approximately 200,000 patients globally each year. The critical unmet need in refractory/relapsed settings represents a substantial commercial opportunity for innovative therapeutic approaches that can deliver meaningful clinical benefit to therapeutically exhausted patient populations.
Next Steps and Future Development
Lantern plans to continue enrollment in the Phase 1 trial while closely monitoring the responding patient and other potential future patients for durability of response and efficacy signals. The company anticipates providing additional clinical updates as the trial progresses and more patients reach evaluable timepoints.
The complete response achievement positions LP-284 for potential accelerated development pathways and creates opportunities for strategic partnerships as Lantern advances its synthetic lethal portfolio toward later-stage clinical trials.
About LP-284
LP-284 is an investigational next-generation acylfulvene designed to exploit synthetic lethal interactions in cancer cells with DNA damage repair deficiencies. Developed with guidance from Lantern's AI platform RADR®, LP-284 represents a novel therapeutic approach with potential to address critical gaps in the treatment of relapsed or refractory non-Hodgkin's lymphoma and other hematologic malignancies. The compound is currently being evaluated in a Phase 1 clinical trial (NCT06132503) to determine its safety profile, optimal dosing, and potential activity in patients with aggressive NHL subtypes who have failed standard therapies.
LP-284 has received multiple Orphan Drug Designations from the U.S. Food and Drug Administration, including designations for mantle cell lymphoma and high-grade B-cell lymphomas, recognizing its potential to address significant unmet medical needs in rare cancer populations.
About Lantern Pharma
Lantern Pharma (NASDAQ: LTRN) is an AI-driven biotechnology company focused on accelerating and optimizing the discovery, development, and commercialization of cancer therapies. Its proprietary RADR® platform leverages artificial intelligence and machine learning with the aim of uncovering novel therapeutic opportunities, accelerating drug development timelines, and improving patient outcomes. The company's approach combines advanced computational biology with traditional pharmaceutical development to transform how cancer drugs are discovered and developed.
For more information, visit:
- Website: www.lanternpharma.com (http://www.lanternpharma.com/)
- LinkedIn: https://www.linkedin.com/company/lanternpharma/
- X: @lanternpharma (https://twitter.com/LanternPharma
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR ® platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate; our strategic plans to advance the development of our drug candidates and antibody drug conjugate (ADC) development program; estimates regarding the development timing for our drug candidates and ADC development program; expectations and estimates regarding clinical trial timing and patient enrollment; our research and development efforts of our internal drug discovery programs and the utilization of our RADR ® platform to streamline the drug development process; our intention to leverage artificial intelligence, machine learning and genomic data to streamline and transform the pace, risk and cost of oncology drug discovery and development and to identify patient populations that would likely respond to a drug candidate; estimates regarding patient populations, potential markets and potential market sizes; sales estimates for our drug candidates and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others. Any statements that are not statements of historical fact (including, without limitation, statements that use words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "model," "objective," "aim," "upcoming," "should," "will," "would," or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the risk that we may not be able to secure sufficient future funding when needed and as required to advance and support our existing and planned clinical trials and operations, (ii) the risk that observations in preclinical studies and early or preliminary observations in clinical studies do not ensure that later observations, studies and development will be consistent or successful, (iii) the risk that our research and the research of our collaborators may not be successful, (iv) the risk that we may not be successful in licensing potential candidates or in completing potential partnerships and collaborations, (v) the risk that none of our product candidates has received FDA marketing approval, and we may not be able to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for our product candidates, (vi) the risk that no drug product based on our proprietary RADR ® AI platform has received FDA marketing approval or otherwise been incorporated into a commercial product, and (vii) those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission on March 27, 2025. You may access our Annual Report on Form 10-K for the year ended December 31, 2024, under the investor SEC filings tab of our website at www.lanternpharma.com (http://www.lanternpharma.com/) or on the SEC's website at www.sec.gov (http://www.sec.gov/). Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
36 minutes ago
- Yahoo
Pony.ai Kicks Off 24/7 Robotaxi Service In Guangzhou And Shenzhen
Pony AI (NASDAQ:PONY) launched 24/7 Robotaxi operations on Friday in Guangzhou and Shenzhen, significantly expanding its service hours in two of China's most dynamic economic hubs. This shift marks a key milestone in the company's Chinese expansion, increasing availability from 15 hours daily to full round-the-clock access. also extended its Robotaxi testing in Beijing to 24 hours a day. Backed by over 50 million kilometers of global autonomous driving tests, has validated its systems across various traffic and lighting conditions, from midday congestion to late-night proprietary 'virtual driver' has completed more than 500,000 hours of driverless operation, achieving a safety record reportedly up to ten times better than human drivers. The company's perception capabilities rely on a fusion of 128-beam LiDAR, 8-megapixel cameras, and 4D imaging millimeter-wave radar, enabling 360-degree, real-time awareness, even in low-light settings. advanced software stack, built on its PonyWorld foundation model, supports its seventh-generation Robotaxi fleet with high-precision detection of road features and obstacles, even up to 650 meters away. Earlier this week, commenced road testing of its Gen-7 BAIC Robotaxis in Beijing, with plans to extend these trials to Guangzhou and Shenzhen. The company surpassed 2 million km in Level 4 controller testing, cut costs by 80%, and reaffirmed plans to mass-produce 1,000 vehicles in 2025. shares surged over 106% over the past three months, far outperforming the over 11% gain in the NASDAQ Golden Dragon China Index. However, the stock gained just 0.7% year-to-date, lagging the index's 15%. In July, short seller Grizzly Research accused the company of falsifying autonomous driving data, using misleading marketing tactics, and falling behind competitors in service quality. The report also raised concerns about financial health, heavy reliance on Chinese state support, and doubts over a rumored U.S. partnership. In response, pointed to recent milestones, including the mass production of its Gen-7 Robotaxi and plans to expand its autonomous fleet to 1,000 vehicles by 2025. In a related development, Lucid Group (NASDAQ:LCID) interim CEO Marc Winterhoff praised the rapid progress of Chinese EVs and Robotaxis, calling their quality impressive, but maintained that Lucid still leads in ride comfort and driving dynamics. He confirmed Lucid would launch its Robotaxi operations in a U.S. city first, even as China continues to advance. Meanwhile, Lucid plans to deploy over 20,000 Robotaxis with Uber Technologies (NYSE:UBER) over six years. Price Action: PONY stock is trading higher by 2.77% to $14.85 premarket at last check Friday. Photo by Tada Images via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Kicks Off 24/7 Robotaxi Service In Guangzhou And Shenzhen originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.
Yahoo
42 minutes ago
- Yahoo
With 80% institutional ownership, Axon Enterprise, Inc. (NASDAQ:AXON) is a favorite amongst the big guns
Key Insights Institutions' substantial holdings in Axon Enterprise implies that they have significant influence over the company's share price A total of 17 investors have a majority stake in the company with 50% ownership Insiders have been selling lately AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Every investor in Axon Enterprise, Inc. (NASDAQ:AXON) should be aware of the most powerful shareholder groups. And the group that holds the biggest piece of the pie are institutions with 80% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). Since institutional have access to huge amounts of capital, their market moves tend to receive a lot of scrutiny by retail or individual investors. Therefore, a good portion of institutional money invested in the company is usually a huge vote of confidence on its future. In the chart below, we zoom in on the different ownership groups of Axon Enterprise. Check out our latest analysis for Axon Enterprise What Does The Institutional Ownership Tell Us About Axon Enterprise? Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing. We can see that Axon Enterprise does have institutional investors; and they hold a good portion of the company's stock. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Axon Enterprise, (below). Of course, keep in mind that there are other factors to consider, too. Investors should note that institutions actually own more than half the company, so they can collectively wield significant power. We note that hedge funds don't have a meaningful investment in Axon Enterprise. The Vanguard Group, Inc. is currently the company's largest shareholder with 11% of shares outstanding. With 9.3% and 4.0% of the shares outstanding respectively, BlackRock, Inc. and State Street Global Advisors, Inc. are the second and third largest shareholders. Additionally, the company's CEO Patrick Smith directly holds 3.9% of the total shares outstanding. Looking at the shareholder registry, we can see that 50% of the ownership is controlled by the top 17 shareholders, meaning that no single shareholder has a majority interest in the ownership. Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. Quite a few analysts cover the stock, so you could look into forecast growth quite easily. Insider Ownership Of Axon Enterprise The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO. I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions. Our most recent data indicates that insiders own some shares in Axon Enterprise, Inc.. It is a very large company, and board members collectively own US$2.6b worth of shares (at current prices). It is good to see this level of investment. You can check here to see if those insiders have been buying recently. General Public Ownership With a 15% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Axon Enterprise. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders. Next Steps: I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Case in point: We've spotted 2 warning signs for Axon Enterprise you should be aware of. If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
42 minutes ago
- Yahoo
Investors in Monolithic Power Systems (NASDAQ:MPWR) have seen strong returns of 180% over the past five years
When you buy a stock there is always a possibility that it could drop 100%. But on the bright side, you can make far more than 100% on a really good stock. Long term Monolithic Power Systems, Inc. (NASDAQ:MPWR) shareholders would be well aware of this, since the stock is up 170% in five years. It's also good to see the share price up 22% over the last quarter. But this could be related to the strong market, which is up 16% in the last three months. So let's investigate and see if the longer term performance of the company has been in line with the underlying business' progress. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. To paraphrase Benjamin Graham: Over the short term the market is a voting machine, but over the long term it's a weighing machine. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS). During five years of share price growth, Monolithic Power Systems achieved compound earnings per share (EPS) growth of 70% per year. This EPS growth is higher than the 22% average annual increase in the share price. So one could conclude that the broader market has become more cautious towards the stock. The company's earnings per share (over time) is depicted in the image below (click to see the exact numbers). We know that Monolithic Power Systems has improved its bottom line over the last three years, but what does the future have in store? Take a more thorough look at Monolithic Power Systems' financial health with this free report on its balance sheet. What About Dividends? It is important to consider the total shareholder return, as well as the share price return, for any given stock. The TSR is a return calculation that accounts for the value of cash dividends (assuming that any dividend received was reinvested) and the calculated value of any discounted capital raisings and spin-offs. Arguably, the TSR gives a more comprehensive picture of the return generated by a stock. As it happens, Monolithic Power Systems' TSR for the last 5 years was 180%, which exceeds the share price return mentioned earlier. This is largely a result of its dividend payments! A Different Perspective While the broader market gained around 19% in the last year, Monolithic Power Systems shareholders lost 12% (even including dividends). Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. On the bright side, long term shareholders have made money, with a gain of 23% per year over half a decade. It could be that the recent sell-off is an opportunity, so it may be worth checking the fundamental data for signs of a long term growth trend. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Even so, be aware that Monolithic Power Systems is showing 3 warning signs in our investment analysis , and 2 of those don't sit too well with us... We will like Monolithic Power Systems better if we see some big insider buys. While we wait, check out this free list of undervalued stocks (mostly small caps) with considerable, recent, insider buying. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
